X

AggregoTV

Top Videos
ESMO Vision stories of Integrated Cancer Care: Verna Vanderpuye, Ghana

"I think ESMO is poised to do that and I think we have a bright future ahead of us," says ESMO member Verna Vanderpuye from Ghana.

10/23/2020
What is the Evidence that Fecal Microbiota Transplantation Can Cure GvHD?

Mette Hazenberg, Amsterdam UMC discusses evidence that fecal microbiota transplantation can cure GvHD.

12/14/2020

AggregoTV

Leukemia, Lymphoma, Myeloma, and Immunotherapy with Dr. Philip Greenberg

Dr. Philip Greenberg discusses how immunotherapy works for blood cancers, promising immunotherapy clinical trials, as well as potential side effects.

12/11/2020
ESMO Vision Stories of Sustainable Cancer Care: Andrea Sbrana

Is statistically significant the same as clinically significant? The ESMO-MCBS has been thought to try and answer this question even when talking about newer treatments, explains Andrea Sbrana.

12/17/2020
`
Colorectal Cancer and Immunotherapy with Dr. Scott Kopetz

Dr. Scott Kopetz discusses the latest breakthroughs and future promise of immunotherapy for colorectal cancer patients.

12/11/2020
What is the Evidence that Fecal Microbiota Transplantation Can Cure GvHD?

Mette Hazenberg, Amsterdam UMC discusses evidence that fecal microbiota transplantation can cure GvHD.

12/14/2020

AggregoTV - AML

An update on the NCRI AML20 trial

Charles Craddock describes the three main questions the trial aims to address, including whether the addition of venetoclax can improve the activity of CPX-351 in adults with AML.

10/21/2020
High Dose Therapy and Autologous Stem Cell Transplantation
red blood cells

Discussion on high dose therapy and autologous stem cell transplantation.

What Are the Goals of AML Treatment?

Dr. Pinkal Desai defines the role of remission and the specific goals of treatment for AML patients.

11/19/2020
Understanding Risk in AML: How Molecular Testing Affects Treatment Options

How does molecular testing impact AML treatment options? Dr. Pinkal Desai discusses molecular testing and how results may help determine the best treatment path for patients.

11/19/2020
What is new in targeted therapies for AML?

Dr. Navel Daver discusses the use of single agents, such as the FLT3 inhibitor, gilteritinib, and the IDH1 inhibitor, ivosidenib, as well as the outcomes of more recent combination treatments with

10/19/2020

AggregoTV - NSCLC

Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Dr Patrick Y. Wen discusses adjuvant osimertinib in resected EGFR-Mutated NSCLC.

05/01/2021
NERO Trial: PARP Inhibitors for Chemosensitive NSCLC

Dr Dean Fennell shares an update on the randomized Phase II/III NERO study investigating PARP inhibitors in patients with NSCLC who have previously responded to chemotherapy.

04/20/2021
Multisystem Immune-Related AEs With Immunotherapy in NSCLC

Jarushka Naidoo gives an overview of a study investigating immune-related adverse events associated with immune checkpoint inhibitor therapy for the treatment of NSCLC.

04/26/2021
No One Missed—NSCLC Biomarker Testing

Dr Jorge Gomez and Andrea Ferris discuss "No One Missed", a new campaign to raise awareness about comprehensive biomarker testing which can reveal vital information that can help identify the appropriate treatment...

05/03/2021
Novel Therapies on the Horizon for Lung Cancer

Dr Samreen Ahmed discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer.

04/29/2021

AggregoTV - DLBCL

Outcomes of CAR-T Therapy in Patients With Refractory B-Cell Lymphoma

Dr Bruce Levine reports on the outcomes for refractory B-cell Lymphoma patients with CAR T-cell therapy.

04/23/2021
Ibrutinib Therapy Prior to Tisa-Cel in R/R DLBCL

Dr Frederick Locke discusses the results of a Phase Ib safety trial of tisagenlecleucel in combination with ibrutinib, a BTK inhibitor, in R/R diffuse large B-cell lymphoma patients.

12/16/2020
Alexander Study: CD19/22 Dual Targeting CAR T-Cell Therapy With Pembrolizumab in R/R DLBCL

During the ASCO Annual Meeting, the Lymphoma Hub speaks to Dr Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

06/02/2020
Is Mosunetuzumab Safe and Effective for Elderly Patients With Untreated DLBCL?

Dr Olszewski reports the results of a phase I/II clinical trial of mosunetuzumab as a first-line treatment for elderly and unfit patients with diffuse large B-cell lymphoma.

12/17/2020
Changes in the Classification of DLBCL

Dr Andrew Davies discusses heterogeneity within diffuse large B-cell lymphoma and how molecular profiling of tumor clones can allow reclassification of the disease.

06/22/2020

AggregoTV - Sickle Cell Anemia

Sickle Cell, COVID-19 and Vaccination

The Sickle Cell Society joins with clinicians and sickle cell patients from across the country to learn more about sickle cell and COVID-19 and to ask questions about the vaccines.

01/29/2021
Pediatric Nursing - Epistaxis, Iron Deficiency Anemia, Sickle Cell Anemia and Hemophilia

Cathy Parkes, BSN, RN, discusses various bleeding disorders in children.

03/19/2021
Loyola Medicine's Sickle Cell Anemia Program

Gail Kellberg, director of Loyola Medicine's sickle cell anemia program and Dr Kevin Smith discuss the program, specifically designed for the needs of the sickle cell patient population.

04/22/2021
COVID-19 Vaccine Spotlight on Sickle Cell Disease

Dr Titilope Fasipe, Co-Director of Texas Children’s Sickle Cell and Thalassemia Program, answers some of the most common questions about the COVID-19 vaccine and sickle cell disease.

02/08/2021
NEET PG-Topic-Sickle Cell Anemia-Obstetrics & Gynecology

Sickle cell disease is the most common hemoglobinopathy encountered during pregnancy.

12/22/2020
Spotlight
Colorectal Cancer and Immunotherapy with Dr. Scott Kopetz

Dr. Scott Kopetz discusses the latest breakthroughs and future promise of immunotherapy for colorectal cancer patients.

12/11/2020

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39